JPWO2020070506A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020070506A5 JPWO2020070506A5 JP2021518512A JP2021518512A JPWO2020070506A5 JP WO2020070506 A5 JPWO2020070506 A5 JP WO2020070506A5 JP 2021518512 A JP2021518512 A JP 2021518512A JP 2021518512 A JP2021518512 A JP 2021518512A JP WO2020070506 A5 JPWO2020070506 A5 JP WO2020070506A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- overtraining
- composition according
- formula
- hydroxybutyrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 5
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical class C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- HIWZHLUXGVVBPK-NZSKALFASA-N (3r)-butane-1,3-diol;(3r)-3-hydroxybutanoic acid Chemical group C[C@@H](O)CCO.C[C@@H](O)CC(O)=O HIWZHLUXGVVBPK-NZSKALFASA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 claims 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 claims 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 claims 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 claims 1
- 206010056474 Erythrosis Diseases 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 238000006384 oligomerization reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816196.8A GB2577723A (en) | 2018-10-04 | 2018-10-04 | Compounds for new use |
| GB1816196.8 | 2018-10-04 | ||
| PCT/GB2019/052797 WO2020070506A1 (en) | 2018-10-04 | 2019-10-03 | Compounds for use in preventing or treating athlete overtraining |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022504207A JP2022504207A (ja) | 2022-01-13 |
| JP2022504207A5 JP2022504207A5 (https=) | 2022-09-22 |
| JPWO2020070506A5 true JPWO2020070506A5 (https=) | 2022-09-22 |
| JP7575163B2 JP7575163B2 (ja) | 2024-10-29 |
Family
ID=68242730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518512A Active JP7575163B2 (ja) | 2018-10-04 | 2019-10-03 | アスリートのオーバートレーニングの予防又は処置に用いる化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12290496B2 (https=) |
| EP (1) | EP3860584B1 (https=) |
| JP (1) | JP7575163B2 (https=) |
| KR (1) | KR102868881B1 (https=) |
| CN (1) | CN112996498B (https=) |
| AU (1) | AU2019351925B2 (https=) |
| CA (1) | CA3114889A1 (https=) |
| GB (2) | GB2577723A (https=) |
| WO (1) | WO2020070506A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100020441A1 (it) | 2021-07-30 | 2023-01-30 | Unichem Estense S R L | Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici |
| CN118591523A (zh) * | 2021-11-12 | 2024-09-03 | 阿萨达股份公司 | 多元醇衍生的化合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090253781A1 (en) | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| EP1648952B1 (en) * | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| SE0400355D0 (sv) | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
| WO2006020137A2 (en) | 2004-07-16 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric compounds |
| EP1778615A4 (en) | 2004-07-20 | 2010-01-06 | Btg Int Ltd | OLIGOMERE KETONE COMPOUNDS |
| CN100344280C (zh) * | 2005-08-01 | 2007-10-24 | 清华大学 | 3－羟基丁酸及其衍生物的新用途 |
| WO2008110034A1 (en) | 2007-03-14 | 2008-09-18 | Shantou University | 3-hydroxy fatty acid and its derivatives for improving of learning and/or memory of subjects |
| EP2240017B1 (en) | 2008-01-04 | 2019-03-13 | Oxford University Innovation Limited | Ketone bodies and ketone body esters as blood lipid lowering agents |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| JP5773870B2 (ja) | 2008-08-21 | 2015-09-02 | アイシス イノヴェイション リミテッド | ヒドロキシ酪酸エステル及びその医学的使用 |
| US8865641B2 (en) | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
| GB201206192D0 (en) * | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
| GB2515603B (en) | 2013-03-14 | 2015-10-14 | Isis Innovation | Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate |
| CA2902603C (en) | 2013-03-19 | 2021-03-02 | University Of South Florida | Compositions and methods for producing elevated and sustained ketosis |
| US11814664B2 (en) | 2013-05-24 | 2023-11-14 | Genomatica, Inc. | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate |
| GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
| US20150283163A1 (en) * | 2014-04-04 | 2015-10-08 | Organic Medical Ventures, L.L.C. | Muscle treatment composition and method making same |
| US20180008629A1 (en) | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CA3021784A1 (en) | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| GB201710229D0 (en) | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
-
2018
- 2018-10-04 GB GB1816196.8A patent/GB2577723A/en not_active Withdrawn
-
2019
- 2019-10-03 US US17/282,594 patent/US12290496B2/en active Active
- 2019-10-03 KR KR1020217013546A patent/KR102868881B1/ko active Active
- 2019-10-03 CN CN201980065370.4A patent/CN112996498B/zh active Active
- 2019-10-03 JP JP2021518512A patent/JP7575163B2/ja active Active
- 2019-10-03 AU AU2019351925A patent/AU2019351925B2/en active Active
- 2019-10-03 EP EP19787377.1A patent/EP3860584B1/en active Active
- 2019-10-03 GB GB2105967.0A patent/GB2592803B/en active Active
- 2019-10-03 WO PCT/GB2019/052797 patent/WO2020070506A1/en not_active Ceased
- 2019-10-03 CA CA3114889A patent/CA3114889A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527547A5 (https=) | ||
| KR20120011031A (ko) | 아세틸살리실산과 테아닌의 수용성 공결정을 이용한 정맥내 투여 제제 | |
| JP2021525775A5 (https=) | ||
| US20160256428A1 (en) | Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis | |
| DK2310020T3 (en) | PRESENT UNKNOWN ACETATES OF 2-DEOXY MONOSACCHARIDES WITH ANTICANCER ACTIVITY | |
| EP3527206A2 (en) | Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound | |
| JP2022504207A5 (https=) | ||
| TW202416965A (zh) | 吡唑并嘧啶化合物及其醫藥用途 | |
| RU2019108824A (ru) | Соединения для лечения заболеваний, связанных с дисфункцией митохондрий | |
| JP2024037922A (ja) | 急性放射線症候群を予防又は処置するための組成物 | |
| JPWO2020070506A5 (https=) | ||
| JP2001518882A (ja) | ホウ素炭水化物錯体及びこれらの使用 | |
| GB2592803A (en) | Compounds for use in preventing or treating athlete overtraining | |
| US9809615B2 (en) | Anti-cancer compounds from invasive salvinias and methods of treating cancer | |
| ES2509143T3 (es) | Tratamiento de una septicemia con 5-etil-1-fenil-2(1H)-piridona | |
| WO1998039291A1 (fr) | Composes | |
| FR3022458A1 (fr) | Utilisation du mannosylglycerate et ses derives comme agent immunostimulant | |
| US11001573B2 (en) | Citric acid derivative | |
| JP7105916B2 (ja) | グリセロール誘導体、これの製造方法及びこれを有効成分として含有する免疫調節剤 | |
| JPWO2019234402A5 (https=) | ||
| FR3110836A1 (fr) | Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence | |
| Julu et al. | Comparison of short-term effects of insulin and essential fatty acids on the slowed nerve conduction of streptozotocin diabetes in rats | |
| US11413254B2 (en) | Application for (2R, 4R)-1,2,4-trihydroxyheptadec-16-yne in preparation of pharmaceutical composition for preventing or treating hepatic injury | |
| KR102658030B1 (ko) | 탈염 함초 추출물 또는 이의 분획물을 포함하는 골 질환 또는 갱년기 질환 예방, 치료 또는 개선용 조성물 및 이의 제조 방법 | |
| WO2025158806A1 (ja) | 代謝機能不全に関連した脂肪性肝疾患の予防又は改善剤 |